Page 74 - pdf_publisher2_project

ющие его эффективность, и существуют только у этого средства две лекарственные формы: инъек ционная и пероральная, первая из которых позво ляет добиться при необходимости быстрого эффе кта, а вторая — проводить долговременную под держивающую терапию в амбулаторных условиях и тем самым повысить качество жизни больного (уменьшение болей), уменьшить потребность при менения наркотических и ненаркотических аналь гетиков, частоту возникновения костных перело мов и увеличить продолжительность жизни.

ЛИТЕРАТУРА:

1. Модников О.П., Новиков Г.А., Родионов В.В. Костные метастазы рака молочной железы. //М. — 256 с. 2. Юрьева Э.А., Матковская Т.А., Елагина И.А., Столяров Ю.Ю. Бисфосфонаты в фармакотерапии костных забо леваний. //Экспериментальная и клиническая фармако логия. — 2000. — том 63. — С.74 79.

3. Body J.J. Bisphosphonates as chemotherapeutic agents. // Current opinion in oncologic,endocrine&metabolic investi gational drugs. — 2000. — Vol.2. — P.155 181.

4. Bonabello A., Galmozzi M.R., Bruzzese T., Zara G.P. Anal gesic effect of bisphosphonates in mice. //Pain. — 2001. — Vol.91. — P.269 275.

5. Boissier S., Magnetto. S., Frappart L., et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmin eralized and mineralized bone extracellular matrix. //Cancer res. — 1997. — Vol.57. — P.3890 3894.

6. Diel I.J. Antitumor effects of bisphosphnates. //Drugs. — 2000. — Vol.59. — P.391 399.

7. Frith J.C., Monkkonen J., Blackburn G.M., et al. Clodronate and liposome encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5 (beta, gamma dichlormethyl ene triphosphate, by mammalian cells in vitro. //J.Bone Mineral.Res. — 1997. — Vol.12. — P.1358 1367.

8. Fernandez Conde M. et al. Skeletal response to clodronate in prostate cancer with bone metastases. //Am. J. C. Oncol. — 1997. — Vol.20. — P.471 476.

9. Gnudi S., Lisi L., Fini M., Malavatova N. Effect of intramus cular clodronate on bone mass and metabolism in osteoporot ic women. //Int.J.Tissue react. — 2001. —Vol. 23. —P.33 37. 10. Heidenreich A., Hofmann R., Engelmann U.H. The use bis phosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. // J.Urol. — 2001. — Vol.165. — P.136 140.

11. Hughes D.E., Wright K.R., Uy H.L., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. // J.Bone Miner.Res. — 1995. — Vol.10. — P.1478 1487. 12. Jung A., Bomand J., Mermillod B. et al. Inhibition by diphos phonate of bone resorption induced by the Wolker tumor of the rat. //Cancer Res. — 1984. — Vol.44. — P.3007 3011. 13. Kanis J.A., PowlesT., Paterson A.H.G. et al., Clodronat decreases the frequency of skeletal metastases in women with breast cancer. //Bone. — 1996. — Vol.19. — P. 663 667. 14. Kanis et al, Consequences of neoplasia induced bone resorp tion and the use of clodronate. (Review). //International Journal of Оncology. — 1994. — Vol.5. — P. 713 731. 15. Kanis J.A., McCloskey E.V. Bisphosphonates in Multiple Myeloma. //Cancer. — 2000. — Vol.88. — P.3022 3032. 16. Krempien B. Morphological findings in bone metastasis, tumorosteopathy and antiosteolytic therapy. //In:Diel I.J., Kaufmann M., Bastert G., editors. —Metastatic bone disease: fundamental and clinical aspects. — Berlin:Springer. — 1994. — P.59 85.

17. Krempiewn B. Experimental findings on the osteoprotective potential of bisphosphonates againist bone metastases and

tumor induced osteopathy; a pleading for an early and pre ventive administration. //In: Orr F.W., Singh G, editors. — Bone metastasis — mechanisms and pathophysiology. — Georgetown (TX): RG Landes. — 1996. — P.221 244. 18. Lachtinen R., Laakso M., Palva I. et al. Randomized placebo controlled multicentre trial of clodronate in multiple myelo ma. //Lancet. — 1992. — Vol.340. — P.1049 1052. 19. Lipton A. Bisphosphonates and Breast Carcinoma. //Cancer. — 2000. — Vol.88. — P.3033 3037.

20. Luckman S.P., Hughes D.E., Cxon F.P. et al. Nitrogen con taining bisphpsphpnates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP binding pro teins. //J.Bone Miner.Res. — 1998. — Vol.13. — P.681 589. 21. Mackie P.S., Fisher J.L., Zhou H., Choong P.F.M. Bisphos phonates regulate cell grouth and gene expression in the UMR 106 01 clonal rat osteosarcoma cell line. //British J. Cancer. — 2001. — Vol.84. — P.951 958.

22. McCloskey E.V., Guest J.F., Kanis J.A. The clinical and cost considerations of bisphosphonates in preventing bone compli cations in patients with metastatic breast cancer or multiple myeloma. //Drugs. — 2001. — Vol.61. — P.1253 1274. 23. McCloskey E.V., Maclennan I.C.M., Drayson M. et al. A randomized trial of the effect of clodronate on skeletal mor bidity in myelomatosis. //Br.J.Haematol. — 1998. — Vol.100. — P.317 325.

24. Mundy G.R., Mechanism of osteolytic bone destruction. //Bone. — 1991. — Vol.12. — P.1 6.

25. MuratoreM., Santacesaria G., Quarta E. et al. Prevention with clodronate of osteoporosis secondary to inhaled corticosteroid treatment in patients with chronic asthmatic bronchitis.// Int.J.Clin.Pharmacol.Res. — 2000. — Vol.20. — p.61 64. 26. Monkholnen J., Taskinen M., Auriola S.O.K. et al. Growth inhibition of macrophage like and other cell types by lipo some encapsulated, calcium bound, and free bisphosphonates in vitro. //J.Dtrug.Target. — 1994. — Vol.2. — P.299 308. 27. O'Rourke et al. Effective treatment of malignant hypercal caemia with a single intravenous infusion of clodronate.// British Journal of Cancer. — 1993. — Vol. 67. — P. 560 563. 28. Paterson A.H.G., Powles T., Kanis J. et al. Double blind con trolled trial of oral clodronate in patients with bone metastases from breast cancer. //Journal of Clinical Oncology. — 1993. — Vol.11. — P. 59 65.

29. Powles T.J., Paterson A.H.G., Nevantaus A., et al. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer (abstract). // Proc. Am. Soc Clin Oncol. — 1998. — Vol.17. — P.468. 30. Reitsma P.H., Teitelbaum S.L., Bijvoet O.L.M. et al. Differ ential action of the bisphosphonates on rat macrophage mediated bone resorption in vitro. //J.clin Invest. — 1982. — Vol.70. — p.927 933.

31. Rogers M.J., Frith J.C., Luckman S.P. et al. Molecular mech anism of action of bisphosphonates. //Bone. — 1999. — Vol.24. — P.S73 S79.

32. Saarto T. et al., Clodronate improves bone mineral density in post menopausal breast cancer patients, treated with adjuvant antioestrogens. //British Journal of Cancer. — 1997. — Vol.75. — P.602 605.

33. Selander K.S., Monkkonen J., Karhukorpi E.K., et al. Char acteristics of clodronate induced apoptosis in osteoclasts and macrophages. //Mol.Pharmacol. — 1996. — Vol.50. — P.1127 1138.

34. Senaratne S.G., Pirianov G., Mansi J.L., et al. Bisphospho nate induce apoptosis in human breast cancer cell lines.// British J. Cancer. — 2000. — Vol.82. — P.1459 1468. 35. Van der Pluijm G., Vloedgraven H., van Beek E., et al. Bisph posphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. //J.clin Invest. —1996. —Vol.98. —P.698 705.

№ 3(II) 4. 2001 г. Паллиативная медицина и реабилитация

74